EORTC Bladder Cancer Risk Calculator

The EORTC risk tables estimate recurrence and progression after transurethral resection in patients with non-muscle-invasive bladder cancer. The model uses six features: number of tumors, largest tumor diameter, prior recurrence rate, pathologic T category, concurrent carcinoma in situ, and WHO 1973 tumor grade. Each feature contributes separate points to a recurrence score and a progression score. The total places the patient into a published risk band with probabilities at one and five years. Recurrence means a new bladder tumor after treatment, while progression means development of more advanced disease, typically muscle-invasive disease. Those outcomes are clinically different, so the scoring weights differ. For example, carcinoma in situ and T1 category contribute much more strongly to progression than to recurrence. The displayed percentages reproduce the commonly published EORTC table bands: recurrence totals range from 0 to 17 and progression totals range from 0 to 23. The original tables were developed from patients enrolled in European clinical trials. Many patients received intravesical chemotherapy, relatively few received modern maintenance bacillus Calmette-Guerin schedules, and grading used the 1973 WHO system. Contemporary practice, improved resection, repeat resection, enhanced cystoscopy, new pathology classification, and different intravesical treatments can change observed outcomes. The estimates may therefore overstate or understate risk for an individual treated today. Other models and current guideline risk groups may be more appropriate in particular settings. Use pathology and operative reports when selecting inputs. Tumor count refers to the number present at the evaluated recurrence, diameter refers to the largest lesion, and recurrence rate depends on documented tumor history. Carcinoma in situ should be selected only when confirmed. Grade must be mapped to the WHO 1973 G1, G2, or G3 categories; do not silently substitute a newer low-grade or high-grade label without pathology guidance. The result is intended for shared discussion with a urologist or oncology team. It cannot determine treatment by itself and does not include age, comorbidity, variant histology, lymphovascular invasion, prostatic urethral involvement, adequacy of resection, or response to prior therapy. Urgent symptoms and treatment decisions require direct clinical care.